• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Life Sciences Investor Forum Agenda Announced for June 11th-12th

    6/10/25 2:38:09 PM ET
    $ATNM
    $BPTH
    $COCH
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNM alert in real time by email

    NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Small Cap Research.

    Individual investors, institutional investors, advisors, and analysts are invited to attend.

    REGISTER HERE

    It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management.

    "The life sciences sector is driving breakthrough innovation, and we're proud to give these pioneering companies a direct line to investors," said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. "This Virtual Investor Conference, co-hosted by Zacks Small Cap Research, offers an essential platform for companies to share their vision, showcase scientific progress, and connect with a wider investment community actively seeking the next wave of healthcare and biotech leaders."

    June 11th

    Eastern

    Time (ET)
    PresentationTicker(s)
    1:00 PM ETNika Pharmaceuticals(OTCQB:NIKA)
    1:30 PM ETTivic Health Systems Inc.(NASDAQ:TIVC)
    2:00 PM ETAdia Nutrition, Inc.(OTCQB:ADIA)
    2:30 PM ET Sandoz Group AG(OTCQX:SDZNY, SIX: SDZ))



    June 12
    th

    Eastern

    Time (ET)
    PresentationTicker(s)
    9:00 AM ETCSL Ltd.(OTCQX:CSLLY, ASX: CSL))
    9:30 AM ETSharps Technology, Inc.(NASDAQ:STSS)
    10:00 AM ETHeidelberg Pharma AG(XETRA: HPHA)
    10:30 AM ETSBC Medical Group Holdings Incorporated(NASDAQ:SBC)
    11:00 AM ETActinium Pharmaceuticals, Inc.(NYSE:ATNM)
    11:30 AM ETImunon, Inc.(NASDAQ:IMNN)
    12:00 PM ETBio-Path Holdings, Inc.(OTCQB:BPTH)
    12:30 PM ETPerimeter Medical Imaging AI, Inc.(OTCQX:PYNKF, TSXV:PINK)
    1:00 PM ETMetaVia Inc.(NASDAQ:MTVA)
    2:00 PM ETConavi Medical Corp.(OTCQB:CNVIF, TSXV:CNVI)
    2:30 PM ETVycor Medical, Inc.(OTCQB:VYCO)
    3:00 PM ETEnvoy Medical, Inc.(NASDAQ:COCH)
    3:30 PM ETStarpharma Holdings Ltd.(OTCQX:SPHRY, ASX: SPL))



    To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Media Contact: 

    OTC Markets Group Inc. +1 (212) 896-4428, [email protected]

    Virtual Investor Conferences Contact:

    John M. Viglotti

    SVP Corporate Services, Investor Access

    OTC Markets Group

    (212) 220-2221

    [email protected]



    Primary Logo

    Get the next $ATNM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATNM
    $BPTH
    $COCH
    $IMNN

    CompanyDatePrice TargetRatingAnalyst
    MetaVia Inc.
    $MTVA
    12/30/2024$12.00Buy
    H.C. Wainwright
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    8/7/2024$16.00 → $2.00Buy → Neutral
    B. Riley Securities
    Envoy Medical Inc.
    $COCH
    6/24/2024$8.50Buy
    Ascendiant Capital Markets
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    5/14/2024$25.00Overweight
    Stephens
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    9/6/2023$11.60Buy
    HSBC Securities
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    2/21/2023Outperform → Mkt Perform
    William Blair
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    9/8/2022$20.00Overweight
    Cantor Fitzgerald
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    8/25/2022$16.00Buy
    B. Riley Securities
    More analyst ratings

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Financials

    Live finance-specific insights

    See more
    • Bio-Path Holdings Provides Clinical and Operational Update

      HOUSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced highlights from the recent clinical development and operational update conference call and webcast held May 26, 2025. An archived webcast of the event can be accessed here. "Our business model centers around generating new drug candidates from our DNAbilize® platform and licensing them for final development and commercialization with partners that have expertise and scale to successfully bring them to market," sa

      6/3/25 7:00:00 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025

      HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced that it will host a live conference call and audio webcast on Thursday, May 29, 2025 at 8:30 a.m. ET to provide a comprehensive business overview. To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company's website, www.biopathho

      5/22/25 4:30:00 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tivic Reports First Quarter 2025 Financial Results and Provides Updates on Business Transformation

      Pre-recorded Conference Call to Follow at 1:30 p.m. PDT/4:30 p.m. EDT Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced financial results for the first quarter ended March 31, 2025 and outlined operational highlights based on its newly expanded clinical pipeline. "This is a defining time for the company. During the quarter we initiated a significant strategic shift, dramatically expanding Tivic's clinical pipeline for restoring immune system health," stated Tivic CEO Jennifer Ernst. "In February, we executed a comprehensive worldwide exclusive licensing agreement for the Phase III TLR5 agonist, Entolimod and its molecular derivative, Ent

      5/15/25 4:05:00 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Leadership Updates

    Live Leadership Updates

    See more
    • Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team

      Handley Joins as President of Tivic Biopharma and Chief Operating Officer of Tivic Health Following Its Licensing of Strategic Biopharma Assets From Statera Biopharma Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to develop and operationalize company-wide strategies. His key responsi

      2/24/25 8:15:00 AM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer

      Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunology LAWRENCEVILLE, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the appointment of Douglas V. Faller, M.D., Ph.D., as chief medical officer, effective February 18, 2025. In this role, Dr. Faller will lead the company's clinical strategy including advancing its lead program IMNN-001 for the treatment of newly diagnosed advanced ovarian cancer, which is on track to enter a Phase 3 pivotal trial in the first quarter of 202

      2/10/25 8:05:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

      -       Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors   -       Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu

      11/4/24 7:30:00 AM ET
      $ATNM
      $AVTX
      $RDHL
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Imunon Inc.

      DEF 14A - Imunon, Inc. (0000749647) (Filer)

      6/9/25 4:30:21 PM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Imunon Inc. filed SEC Form 8-K: Other Events

      8-K - Imunon, Inc. (0000749647) (Filer)

      6/9/25 2:35:19 PM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-1 filed by Tivic Health Systems Inc.

      S-1 - Tivic Health Systems, Inc. (0001787740) (Filer)

      6/6/25 4:34:55 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Patel Mona Chetan bought $14,600 worth of shares (10,000 units at $1.46), increasing direct ownership by 133% to 17,500 units (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      6/10/25 4:11:23 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Chief Executive Officer Lucas Brent T. was granted 12,907 shares, increasing direct ownership by 6% to 216,485 units (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      6/9/25 8:58:13 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Chief Financial Officer Woodworth Marshall H bought $9,940 worth of shares (14,200 units at $0.70), increasing direct ownership by 47% to 44,279 units (SEC Form 4)

      4 - MetaVia Inc. (0001638287) (Issuer)

      6/4/25 4:01:12 PM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Envoy Medical to Present at the Life Sciences Virtual Investor Forum June 12th

      WHITE BEAR LAKE, Minn., June 11, 2025 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announced that Brent Lucas, CEO of Envoy Medical, will present live at the Life Sciences Virtual Investor Frum hosted by VirtualInvestorConferences.com, on June 12th, 2025. DATE: June 12th TIME: 3pm EasternLINK: REGISTER HEREAvailable for 1x1 meetings: June 12th through the 17th This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the da

      6/11/25 8:30:00 AM ET
      $COCH
      Industrial Specialties
      Health Care
    • Life Sciences Investor Forum Agenda Announced for June 11th-12th

      NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. "The life sciences sector is driving breakthrough innovation, and we're proud to give these pioneering co

      6/10/25 2:38:09 PM ET
      $ATNM
      $BPTH
      $COCH
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th

      CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer will present a company overview live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, taking place June 11-12, 2025. DATE: Wednesday June 12, 2025 TIME: 1:00 – 1:30 pm ETLINK: REGISTER HEREAvailable for 1x1 meetings: June 12, 13, and 16 This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on t

      6/10/25 8:31:00 AM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on MetaVia with a new price target

      H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00

      12/30/24 7:25:48 AM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinum Pharma downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Actinum Pharma from Buy to Neutral and set a new price target of $2.00 from $16.00 previously

      8/7/24 12:40:34 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ascendiant Capital Markets initiated coverage on Envoy Medical with a new price target

      Ascendiant Capital Markets initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $8.50

      6/24/24 7:29:10 AM ET
      $COCH
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Imunon Inc.

      SC 13G - Imunon, Inc. (0000749647) (Subject)

      11/14/24 5:37:34 PM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Imunon Inc.

      SC 13G/A - Imunon, Inc. (0000749647) (Subject)

      11/14/24 12:17:50 PM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Envoy Medical Inc.

      SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

      11/14/24 8:49:34 AM ET
      $COCH
      Industrial Specialties
      Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Patel Mona Chetan bought $14,600 worth of shares (10,000 units at $1.46), increasing direct ownership by 133% to 17,500 units (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      6/10/25 4:11:23 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Chief Financial Officer Woodworth Marshall H bought $9,940 worth of shares (14,200 units at $0.70), increasing direct ownership by 47% to 44,279 units (SEC Form 4)

      4 - MetaVia Inc. (0001638287) (Issuer)

      6/4/25 4:01:12 PM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Brynelsen Charles bought $82,403 worth of shares (50,000 units at $1.65) (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      5/27/25 6:34:31 PM ET
      $COCH
      Industrial Specialties
      Health Care